Back to resultsTolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema
Primary Purpose
Atopic Dermatitis (AD)
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Experimental Product
Sponsored by
About this trial
This is an interventional treatment trial for Atopic Dermatitis (AD) focused on measuring Eczema, Skin Irritation
Eligibility Criteria
Inclusion Criteria:
- Male or female of any race or ethnicity, 6 months to 36 months of age and/or 18 years and above.
- Adult subjects only - Male or non-pregnant, non-lactating female agree to the contraceptive requirements (including female partners use of a highly effective form of birth control for 3 months.
- Diagnosed as having Eczema.
- Willing to stop the use of any non- assigned moisturizers and/or creams for the entire duration of the study.
- Willing to not introduce any new fragrances (e.g. cleansers, lotions, perfumes, etc.), or in the household environment (e.g. room fresheners, cleansing agents, laundry detergents, etc.) for the duration of the study.
- Willing to avoid excessive (more than 30 minutes) sun exposure without the use of their regular brand of sunscreen and protective clothing.
- Willing to not enter/use hot tub or whirlpool bath for the duration of the study.
- Willing to avoid the beach during the course of the study, and willing to document any activities at or in a swimming pool in the daily diary.
Exclusion Criteria:
- Use of a therapeutic (over the counter or prescription) body wash that contains an active ingredient for eczema.
- Adults Females who are pregnant (self-reported) or breastfeeding.
- Participation in any clinical study within 30 days of Visit 1.
- Atopic Dermatitis requiring systemic, super-potent (Class I) or potent (Class II or III) topical corticosteroids.
- Requires greater than 2.0 mg/day inhaled or intranasal corticosteroids.
- Subjects who exhibit clinically active bacterial, fungal, or viral skin infections or those who are susceptible to cutaneous infections.
- Subjects who are currently on phototherapy.
Sites / Locations
- Hill-top Research, Inc
- TKL Research Inc.
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Adult Tolerance Assessment
Baby (infants, toddlers, young children) Tolerance Assessment
Arm Description
Apply thin layer of experimental product to the affected skin areas at least 2 times per day and massage gently into skin
Apply thin layer of experimental product to the affected skin areas at least 2 times per day and massage gently into skin
Outcomes
Primary Outcome Measures
Percentage With Erythema on the Face at Baseline Before Investigational Product Application
Percentage of adults and babies with erythema on the face at baseline before investigational product application
Percentage With Erythema on the Arms at Baseline Before Investigational Product Application
Percentage of adults and babies with erythema on the arms at baseline before investigational product application
Percentage With Erythema on the Legs at Baseline Before Investigational Product Application
Percentage of adults and babies with erythema on the legs at baseline before investigational product application
Percentage With Erythema on the Torso at Baseline Before Investigational Product Application
Percentage of adults and babies with erythema on the torso at baseline before investigational product application
Percentage With Erythema on the Face at Baseline After Investigational Product Application
Percentage of adults and babies with erythema on the face at baseline after investigational product application
Percentage With Erythema on the Arms at Baseline After Investigational Product Application
Percentage of adults and babies with erythema on the arms at baseline after investigational product application
Percentage With Erythema on the Legs at Baseline After Investigational Product Application
Percentage of adults and babies with erythema on the legs at baseline after investigational product application
Percentage With Erythema on the Torso at Baseline After Investigational Product Application
Percentage of adults and babies with erythema on the torso at baseline after investigational product application
Percentage With Erythema on the Face at Day 1
Percentage of adults and babies with erythema on the face at Day 1
Percentage With Erythema on the Arms at Day 1
Percentage of adults and babies with erythema on the arms at Day 1
Percentage With Erythema on the Legs at Day 1
Percentage of adults and babies with erythema on the legs at Day 1
Percentage With Erythema on the Torso at Day 1
Percentage of adults and babies with erythema on the torso at Day 1
Percentage With Erythema on the Face at Day 7
Percentage of adults and babies with erythema on the face at Day 7
Percentage With Erythema on the Arms at Day 7
Percentage of adults and babies with erythema on the arms at Day 7
Percentage With Erythema on the Legs at Day 7
Percentage of adults and babies with erythema on the legs at Day 7
Percentage With Erythema on the Torso at Day 7
Percentage of adults and babies with erythema on the torso at Day 7
Percentage With Erythema on the Face at Day 14
Percentage of adults and babies with erythema on the face at Day 14
Percentage With Erythema on the Arms at Day 14
Percentage of adults and babies with erythema on the arms at Day 14
Percentage With Erythema on the Legs at Day 14
Percentage of adults and babies with erythema on the legs at Day 14
Percentage With Erythema on the Torso at Day 14
Percentage of adults and babies with erythema on the torso at Day 14
Percentage With Edema on the Face at Baseline Before Investigational Product Application
Percentage of adults and babies with edema on the face at baseline before investigational product application
Percentage With Edema on the Arms at Baseline Before Investigational Product Application
Percentage of adults and babies with edema on the arms at baseline before investigational product application
Percentage With Edema on the Legs at Baseline Before Investigational Product Application
Percentage of adults and babies with edema on the legs at baseline before investigational product application
Percentage With Edema on the Torso at Baseline Before Investigational Product Application
Percentage of adults and babies with edema on the torso at baseline before investigational product application
Percentage With Edema on the Face at Baseline After Investigational Product Application
Percentage of adults and babies with edema on the face at baseline after investigational product application
Percentage With Edema on the Arms at Baseline After Investigational Product Application
Percentage of adults and babies with edema on the arms at baseline after investigational product application
Percentage With Edema on the Legs at Baseline After Investigational Product Application
Percentage of adults and babies with edema on the legs at baseline after investigational product application
Percentage With Edema on the Torso at Baseline After Investigational Product Application
Percentage of adults and babies with edema on the torso at baseline after investigational product application
Percentage With Edema on the Face at Day 1
Percentage of adults and babies with edema on the face at Day 1
Percentage With Edema on the Arms at Day 1
Percentage of adults and babies with edema on the arms at Day 1
Percentage With Edema on the Legs at Day 1
Percentage of adults and babies with edema on the legs at Day 1
Percentage With Edema on the Torso at Day 1
Percentage of adults and babies with edema on the torso at Day 1
Percentage With Edema on the Face at Day 7
Percentage of adults and babies with edema on the face at Day 7
Percentage With Edema on the Arms at Day 7
Percentage of adults and babies with edema on the arms at Day 7
Percentage With Edema on the Legs at Day 7
Percentage of adults and babies with edema on the legs at Day 7
Percentage With Edema on the Torso at Day 7
Percentage of adults and babies with edema on the torso at Day 7
Percentage With Edema on the Face at Day 14
Percentage of adults and babies with edema on the face at Day 14
Percentage With Edema on the Arms at Day 14
Percentage of adults and babies with edema on the arms at Day 14
Percentage With Edema on the Legs at Day 14
Percentage of adults and babies with edema on the legs at Day 14
Percentage With Edema on the Torso at Day 14
Percentage of adults and babies with edema on the torso at Day 14
Percentage With Scaling on the Face at Baseline Before Investigational Product Application
Percentage of adults and babies with scaling on the face at baseline before investigational product application
Percentage With Scaling on the Arms at Baseline Before Investigational Product Application
Percentage of adults and babies with scaling on the arms at baseline before investigational product application
Percentage With Scaling on the Legs at Baseline Before Investigational Product Application
Percentage of adults and babies with scaling on the legs at baseline before investigational product application
Percentage With Scaling on the Torso at Baseline Before Investigational Product Application
Percentage of adults and babies with scaling on the torso at baseline before investigational product application
Percentage With Scaling on the Face at Baseline After Investigational Product Application
Percentage of adults and babies with scaling on the face at baseline after investigational product application
Percentage With Scaling on the Arms at Baseline After Investigational Product Application
Percentage of adults and babies with scaling on the arms at baseline after investigational product application
Percentage With Scaling on the Legs at Baseline After Investigational Product Application
Percentage of adults and babies with scaling on the legs at baseline after investigational product application
Percentage With Scaling on the Torso at Baseline After Investigational Product Application
Percentage of adults and babies with scaling on the torso at baseline after investigational product application
Percentage With Scaling on the Face at Day 1
Percentage of adults and babies with scaling on the face at Day 1
Percentage With Scaling on the Arms at Day 1
Percentage of adults and babies with scaling on the arms at Day 1
Percentage With Scaling on the Legs at Day 1
Percentage of adults and babies with scaling on the legs at Day 1
Percentage With Scaling on the Torso at Day 1
Percentage of adults and babies with scaling on the torso at Day 1
Percentage With Scaling on the Face at Day 7
Percentage of adults and babies with scaling on the face at Day 7
Percentage With Scaling on the Arms at Day 7
Percentage of adults and babies with scaling on the arms at Day 7
Percentage With Scaling on the Legs at Day 7
Percentage of adults and babies with scaling on the legs at Day 7
Percentage With Scaling on the Torso at Day 7
Percentage of adults and babies with scaling on the torso at Day 7
Percentage With Scaling on the Face at Day 14
Percentage of adults and babies with scaling on the face at Day 14
Percentage With Scaling on the Arms at Day 14
Percentage of adults and babies with scaling on the arms at Day 14
Percentage With Scaling on the Legs at Day 14
Percentage of adults and babies with scaling on the legs at Day 14
Percentage With Scaling on the Torso at Day 14
Percentage of adults and babies with scaling on the torso at Day 14
Secondary Outcome Measures
Full Information
NCT ID
NCT02357940
First Posted
February 3, 2015
Last Updated
November 18, 2016
Sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
1. Study Identification
Unique Protocol Identification Number
NCT02357940
Brief Title
Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema
Official Title
Clinical Trial to Evaluate the Tolerance of a Nighttime Moisturizing Balm on Babies and Adults With Mild to Moderate Atopic Dermatitis
Study Type
Interventional
2. Study Status
Record Verification Date
November 2016
Overall Recruitment Status
Completed
Study Start Date
January 2015 (undefined)
Primary Completion Date
January 2016 (Actual)
Study Completion Date
January 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this 14-day, two phase clinical study is to test the tolerance of a new over-the-counter moisturizing balm on subjects with eczema.
Detailed Description
At least 60 subjects will be enrolled to ensure 40 (10 adults and 30 babies) completed subjects. The tolerability of this formulation will be monitored in a small group of ten adult subjects with mild to moderate eczema prior to testing in babies. In Group A, adults will be asked to give their informed consent and an evaluation of inclusion/exclusion criteria will be performed at the site. After screening, all subjects will be asked not to use any skin treatments until the next clinic visit. Subjects will use the investigational product as indicated at least twice per day on the face - cheeks only, arms, legs and torso for 14 days. For both adults and babies, only the baseline measurements are collected at 5-10 minutes after first application, but not at Day 1, Day 7 and Day 14 visits. Babies from 6 to 36 months of age with mild to moderate eczema, who meet the eligibility criteria, will follow a similar testing directions in Group B of the study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atopic Dermatitis (AD)
Keywords
Eczema, Skin Irritation
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
41 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Adult Tolerance Assessment
Arm Type
Experimental
Arm Description
Apply thin layer of experimental product to the affected skin areas at least 2 times per day and massage gently into skin
Arm Title
Baby (infants, toddlers, young children) Tolerance Assessment
Arm Type
Experimental
Arm Description
Apply thin layer of experimental product to the affected skin areas at least 2 times per day and massage gently into skin
Intervention Type
Drug
Intervention Name(s)
Experimental Product
Other Intervention Name(s)
Eczema Moisturizing Balm
Intervention Description
1% Colloidal Oatmeal Balm
Primary Outcome Measure Information:
Title
Percentage With Erythema on the Face at Baseline Before Investigational Product Application
Description
Percentage of adults and babies with erythema on the face at baseline before investigational product application
Time Frame
At baseline before investigational product application
Title
Percentage With Erythema on the Arms at Baseline Before Investigational Product Application
Description
Percentage of adults and babies with erythema on the arms at baseline before investigational product application
Time Frame
At baseline before investigational product application
Title
Percentage With Erythema on the Legs at Baseline Before Investigational Product Application
Description
Percentage of adults and babies with erythema on the legs at baseline before investigational product application
Time Frame
At baseline before investigational product application
Title
Percentage With Erythema on the Torso at Baseline Before Investigational Product Application
Description
Percentage of adults and babies with erythema on the torso at baseline before investigational product application
Time Frame
At baseline before investigational product application
Title
Percentage With Erythema on the Face at Baseline After Investigational Product Application
Description
Percentage of adults and babies with erythema on the face at baseline after investigational product application
Time Frame
At baseline after investigational product application
Title
Percentage With Erythema on the Arms at Baseline After Investigational Product Application
Description
Percentage of adults and babies with erythema on the arms at baseline after investigational product application
Time Frame
At baseline after investigational product application
Title
Percentage With Erythema on the Legs at Baseline After Investigational Product Application
Description
Percentage of adults and babies with erythema on the legs at baseline after investigational product application
Time Frame
At baseline after investigational product application
Title
Percentage With Erythema on the Torso at Baseline After Investigational Product Application
Description
Percentage of adults and babies with erythema on the torso at baseline after investigational product application
Time Frame
At baseline after investigational product application
Title
Percentage With Erythema on the Face at Day 1
Description
Percentage of adults and babies with erythema on the face at Day 1
Time Frame
At Day 1
Title
Percentage With Erythema on the Arms at Day 1
Description
Percentage of adults and babies with erythema on the arms at Day 1
Time Frame
At Day 1
Title
Percentage With Erythema on the Legs at Day 1
Description
Percentage of adults and babies with erythema on the legs at Day 1
Time Frame
At Day 1
Title
Percentage With Erythema on the Torso at Day 1
Description
Percentage of adults and babies with erythema on the torso at Day 1
Time Frame
At Day 1
Title
Percentage With Erythema on the Face at Day 7
Description
Percentage of adults and babies with erythema on the face at Day 7
Time Frame
At Day 7
Title
Percentage With Erythema on the Arms at Day 7
Description
Percentage of adults and babies with erythema on the arms at Day 7
Time Frame
At Day 7
Title
Percentage With Erythema on the Legs at Day 7
Description
Percentage of adults and babies with erythema on the legs at Day 7
Time Frame
At Day 7
Title
Percentage With Erythema on the Torso at Day 7
Description
Percentage of adults and babies with erythema on the torso at Day 7
Time Frame
At Day 7
Title
Percentage With Erythema on the Face at Day 14
Description
Percentage of adults and babies with erythema on the face at Day 14
Time Frame
At Day 14
Title
Percentage With Erythema on the Arms at Day 14
Description
Percentage of adults and babies with erythema on the arms at Day 14
Time Frame
At Day 14
Title
Percentage With Erythema on the Legs at Day 14
Description
Percentage of adults and babies with erythema on the legs at Day 14
Time Frame
At Day 14
Title
Percentage With Erythema on the Torso at Day 14
Description
Percentage of adults and babies with erythema on the torso at Day 14
Time Frame
At Day 14
Title
Percentage With Edema on the Face at Baseline Before Investigational Product Application
Description
Percentage of adults and babies with edema on the face at baseline before investigational product application
Time Frame
At baseline before investigational product application
Title
Percentage With Edema on the Arms at Baseline Before Investigational Product Application
Description
Percentage of adults and babies with edema on the arms at baseline before investigational product application
Time Frame
At baseline before investigational product application
Title
Percentage With Edema on the Legs at Baseline Before Investigational Product Application
Description
Percentage of adults and babies with edema on the legs at baseline before investigational product application
Time Frame
At baseline before investigational product application
Title
Percentage With Edema on the Torso at Baseline Before Investigational Product Application
Description
Percentage of adults and babies with edema on the torso at baseline before investigational product application
Time Frame
At baseline before investigational product application
Title
Percentage With Edema on the Face at Baseline After Investigational Product Application
Description
Percentage of adults and babies with edema on the face at baseline after investigational product application
Time Frame
At baseline after investigational product application
Title
Percentage With Edema on the Arms at Baseline After Investigational Product Application
Description
Percentage of adults and babies with edema on the arms at baseline after investigational product application
Time Frame
At baseline after investigational product application
Title
Percentage With Edema on the Legs at Baseline After Investigational Product Application
Description
Percentage of adults and babies with edema on the legs at baseline after investigational product application
Time Frame
At baseline after investigational product application
Title
Percentage With Edema on the Torso at Baseline After Investigational Product Application
Description
Percentage of adults and babies with edema on the torso at baseline after investigational product application
Time Frame
At baseline after investigational product application
Title
Percentage With Edema on the Face at Day 1
Description
Percentage of adults and babies with edema on the face at Day 1
Time Frame
At Day 1
Title
Percentage With Edema on the Arms at Day 1
Description
Percentage of adults and babies with edema on the arms at Day 1
Time Frame
At Day 1
Title
Percentage With Edema on the Legs at Day 1
Description
Percentage of adults and babies with edema on the legs at Day 1
Time Frame
At Day 1
Title
Percentage With Edema on the Torso at Day 1
Description
Percentage of adults and babies with edema on the torso at Day 1
Time Frame
At Day 1
Title
Percentage With Edema on the Face at Day 7
Description
Percentage of adults and babies with edema on the face at Day 7
Time Frame
At Day 7
Title
Percentage With Edema on the Arms at Day 7
Description
Percentage of adults and babies with edema on the arms at Day 7
Time Frame
At Day 7
Title
Percentage With Edema on the Legs at Day 7
Description
Percentage of adults and babies with edema on the legs at Day 7
Time Frame
At Day 7
Title
Percentage With Edema on the Torso at Day 7
Description
Percentage of adults and babies with edema on the torso at Day 7
Time Frame
At Day 7
Title
Percentage With Edema on the Face at Day 14
Description
Percentage of adults and babies with edema on the face at Day 14
Time Frame
At Day 14
Title
Percentage With Edema on the Arms at Day 14
Description
Percentage of adults and babies with edema on the arms at Day 14
Time Frame
At Day 14
Title
Percentage With Edema on the Legs at Day 14
Description
Percentage of adults and babies with edema on the legs at Day 14
Time Frame
At Day 14
Title
Percentage With Edema on the Torso at Day 14
Description
Percentage of adults and babies with edema on the torso at Day 14
Time Frame
At Day 14
Title
Percentage With Scaling on the Face at Baseline Before Investigational Product Application
Description
Percentage of adults and babies with scaling on the face at baseline before investigational product application
Time Frame
At baseline before investigational product application
Title
Percentage With Scaling on the Arms at Baseline Before Investigational Product Application
Description
Percentage of adults and babies with scaling on the arms at baseline before investigational product application
Time Frame
At baseline before investigational product application
Title
Percentage With Scaling on the Legs at Baseline Before Investigational Product Application
Description
Percentage of adults and babies with scaling on the legs at baseline before investigational product application
Time Frame
At baseline before investigational product application
Title
Percentage With Scaling on the Torso at Baseline Before Investigational Product Application
Description
Percentage of adults and babies with scaling on the torso at baseline before investigational product application
Time Frame
At baseline before investigational product application
Title
Percentage With Scaling on the Face at Baseline After Investigational Product Application
Description
Percentage of adults and babies with scaling on the face at baseline after investigational product application
Time Frame
At baseline after investigational product application
Title
Percentage With Scaling on the Arms at Baseline After Investigational Product Application
Description
Percentage of adults and babies with scaling on the arms at baseline after investigational product application
Time Frame
At baseline after investigational product application
Title
Percentage With Scaling on the Legs at Baseline After Investigational Product Application
Description
Percentage of adults and babies with scaling on the legs at baseline after investigational product application
Time Frame
At baseline after investigational product application
Title
Percentage With Scaling on the Torso at Baseline After Investigational Product Application
Description
Percentage of adults and babies with scaling on the torso at baseline after investigational product application
Time Frame
At baseline after investigational product application
Title
Percentage With Scaling on the Face at Day 1
Description
Percentage of adults and babies with scaling on the face at Day 1
Time Frame
At Day 1
Title
Percentage With Scaling on the Arms at Day 1
Description
Percentage of adults and babies with scaling on the arms at Day 1
Time Frame
At Day 1
Title
Percentage With Scaling on the Legs at Day 1
Description
Percentage of adults and babies with scaling on the legs at Day 1
Time Frame
At Day 1
Title
Percentage With Scaling on the Torso at Day 1
Description
Percentage of adults and babies with scaling on the torso at Day 1
Time Frame
At Day 1
Title
Percentage With Scaling on the Face at Day 7
Description
Percentage of adults and babies with scaling on the face at Day 7
Time Frame
At Day 7
Title
Percentage With Scaling on the Arms at Day 7
Description
Percentage of adults and babies with scaling on the arms at Day 7
Time Frame
At Day 7
Title
Percentage With Scaling on the Legs at Day 7
Description
Percentage of adults and babies with scaling on the legs at Day 7
Time Frame
At Day 7
Title
Percentage With Scaling on the Torso at Day 7
Description
Percentage of adults and babies with scaling on the torso at Day 7
Time Frame
At Day 7
Title
Percentage With Scaling on the Face at Day 14
Description
Percentage of adults and babies with scaling on the face at Day 14
Time Frame
At Day 14
Title
Percentage With Scaling on the Arms at Day 14
Description
Percentage of adults and babies with scaling on the arms at Day 14
Time Frame
At Day 14
Title
Percentage With Scaling on the Legs at Day 14
Description
Percentage of adults and babies with scaling on the legs at Day 14
Time Frame
At Day 14
Title
Percentage With Scaling on the Torso at Day 14
Description
Percentage of adults and babies with scaling on the torso at Day 14
Time Frame
At Day 14
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Months
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Male or female of any race or ethnicity, 6 months to 36 months of age and/or 18 years and above.
Adult subjects only - Male or non-pregnant, non-lactating female agree to the contraceptive requirements (including female partners use of a highly effective form of birth control for 3 months.
Diagnosed as having Eczema.
Willing to stop the use of any non- assigned moisturizers and/or creams for the entire duration of the study.
Willing to not introduce any new fragrances (e.g. cleansers, lotions, perfumes, etc.), or in the household environment (e.g. room fresheners, cleansing agents, laundry detergents, etc.) for the duration of the study.
Willing to avoid excessive (more than 30 minutes) sun exposure without the use of their regular brand of sunscreen and protective clothing.
Willing to not enter/use hot tub or whirlpool bath for the duration of the study.
Willing to avoid the beach during the course of the study, and willing to document any activities at or in a swimming pool in the daily diary.
Exclusion Criteria:
Use of a therapeutic (over the counter or prescription) body wash that contains an active ingredient for eczema.
Adults Females who are pregnant (self-reported) or breastfeeding.
Participation in any clinical study within 30 days of Visit 1.
Atopic Dermatitis requiring systemic, super-potent (Class I) or potent (Class II or III) topical corticosteroids.
Requires greater than 2.0 mg/day inhaled or intranasal corticosteroids.
Subjects who exhibit clinically active bacterial, fungal, or viral skin infections or those who are susceptible to cutaneous infections.
Subjects who are currently on phototherapy.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Amisha Parikh-Das, Ph.D.
Organizational Affiliation
Johnson & Johnson Consumer Inc. (J&JCI)
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Daniel Hogan, M.D.
Organizational Affiliation
Hill-top Research Inc.
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ethlynn Schorr, M.D.
Organizational Affiliation
TKL Research, Inc.
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hill-top Research, Inc
City
St. Petersburg
State/Province
Florida
ZIP/Postal Code
33714
Country
United States
Facility Name
TKL Research Inc.
City
Fair Lawn
State/Province
New Jersey
ZIP/Postal Code
07410
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema
We'll reach out to this number within 24 hrs